RADNOR, Pa., Jan. 5, 2015 /TRENDINGGLOBALNEWS/ -- Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development
of innovative transdermal synthetic cannabinoid treatments, announced
that the appointment of Richard A. Baron
as vice president and chief financial officer (CFO) effective today.
Mr. Baron offers more than 30 years of experience in executive finance
leadership for early-stage, pharmaceutical and healthcare companies.
Prior to joining Zynerba, Mr. Baron served as senior vice president and CFO of Globus Medical (NYSE: GMED), a medical device company with a market cap of more than $2 billion.
He previously served as vice president, finance and chief financial
officer of Avid Radiopharmaceuticals, a biotech company sold to Eli
Lilly in 2011 for $300 million with milestone potential to $800 million.
Mr. Baron also served as CFO for a number of life sciences companies
including Animas Corporation, which was sold to Johnson & Johnson in
2007. He earned a BS in Economics, concentration in Accounting, from
the Wharton School of the University of Pennsylvania.
"Rick
has an exemplary track record of successfully helping emerging
companies grow to the next level through strategic financing," said
Zynerba chairman and chief executive officer Armando Anido.
"He will be a valued member of the Zynerba team as we rapidly approach
clinical development of these novel transdermal synthetic cannabinoid
candidates in the coming months and work to take the company to the next
stage."
source:http://www.prnewswire.com
0 comments:
Post a Comment